data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Unity Biotechnology

(NASDAQ:UBX)

Intraday

$1.51

0.02[1.34%]

After-Hours

$1.51

0[0.00%]

Perks Buy Compare Brokers

$1.51

0.02[1.34%]

At close: Apr 24

$1.51

0[0.00%]

After Hours: 7:36PM EDT

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Unity Biotechnology Stock (NASDAQ:UBX)

Unity Biotechnology Stock (NASDAQ: UBX)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Tuesday, April 23, 2024

UNITY Biotechnology Announces Extension Of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 For Patients In Diabetic Macular Edema
Benzinga Newsdesk - 1 day ago

Wednesday, April 17, 2024

Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Avi Kapoor - Apr 17, 2024, 8:21AM
HC Wainwright & Co. Maintains Buy on Unity Biotechnology, Lowers Price Target to $8
Benzinga Newsdesk - Apr 17, 2024, 5:53AM

Tuesday, April 16, 2024

HC Wainwright & Co. Maintains Buy on Unity Biotechnology, Lowers Price Target to $8
Benzinga Newsdesk - Apr 16, 2024, 7:05AM

Monday, April 15, 2024

Unity Biotechnology's 2023 Cash, Cash Equivalents And Marketable Securities Of $43.2M Is Expected To Fund Operations Into Q3 Of 2025
Benzinga Newsdesk - Apr 15, 2024, 7:23AM
Unity Biotechnology Q4 2023 GAAP EPS $(0.28) May Not Be Comparable To $(0.77) Estimate
Benzinga Newsdesk - Apr 15, 2024, 7:22AM

Monday, March 25, 2024

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Mar 25, 2024, 5:32PM

Tuesday, February 06, 2024

UNITY Biotechnology, Inc. Announces New Publication In Nature Medicine Supports Therapeutic Potential Of Senolytics To Provide Long-lasting, Disease-Modifying Intervention In Vision Loss
Benzinga Newsdesk - Feb 6, 2024, 8:04AM

Friday, January 19, 2024

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Jan 19, 2024, 4:31PM

Tuesday, December 12, 2023

UNITY Biotechnology Announced That The First Patients Have Been Dosed In The Phase 2 ASPIRE Study Of UBX1325, A Bcl-xL Inhibitor Being Evaluated Head-to-head Against Standard Of Care Anti-VEGF In Patients With Diabetic Macular Edema
Benzinga Newsdesk - Dec 12, 2023, 8:04AM

Wednesday, December 06, 2023

Unity Biotechnology Reports Secondary Offering Of Up To $2.27M Shares Of Common Stock - Filing
Benzinga Newsdesk - Dec 6, 2023, 5:32PM

Thursday, November 16, 2023

Unity Biotechnology Upgraded - Analyst Highlights Cash Strength & Execution
Shivani Kumaresan - Nov 16, 2023, 2:41PM
Wedbush Upgrades Unity Biotechnology to Outperform
Benzinga Newsdesk - Nov 16, 2023, 8:03AM

Tuesday, November 14, 2023

HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $10 Price Target
Benzinga Newsdesk - Nov 14, 2023, 7:11AM

Monday, November 13, 2023

UNITY Biotechnology Q3 EPS $(1.05) vs $(1.36) YoY
Benzinga Newsdesk - Nov 13, 2023, 5:18PM

Wednesday, September 27, 2023

UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration
Benzinga Newsdesk - Sep 27, 2023, 7:06AM

Wednesday, August 09, 2023

Analyst Ratings for Unity Biotechnology
Benzinga Insights - Aug 9, 2023, 10:00AM
HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $10 Price Target
Benzinga Newsdesk - Aug 9, 2023, 6:40AM

Tuesday, August 08, 2023

Unity Biotechnology Q2 EPS $(0.85) Beats $(0.86) Estimate
Benzinga Newsdesk - Aug 8, 2023, 6:08PM

Tuesday, June 27, 2023

Board Member at Unity Biotechnology Acquires Company Stock Options Worth 6,000 Shares
Benzinga Insights - Jun 27, 2023, 11:03AM
Unity Biotechnology Board Member Awarded $16K Worth of Stock Options
Benzinga Insights - Jun 27, 2023, 11:02AM
Director at Unity Biotechnology Acquires Company Stock Options Worth 6,000 Shares
Benzinga Insights - Jun 27, 2023, 11:02AM

Monday, June 26, 2023

Benzinga's Top Ratings Upgrades, Downgrades For June 26, 2023
Benzinga Insights - Jun 26, 2023, 11:01AM
The Latest Analyst Ratings for Unity Biotechnology
Benzinga Insights - Jun 26, 2023, 8:00AM
Wedbush Downgrades Unity Biotechnology to Neutral, Lowers Price Target to $2
Benzinga Newsdesk - Jun 26, 2023, 7:05AM

Wednesday, June 21, 2023

Unity Biotechnology Announced Design Of Its Phase 2B Aspire Clinical Trial For UBX1325 (Foselutoclax) Head-to-head Against Aflibercept In Previously Treated Patients With Active Diabetic Macular Edema; First Patient Is Expected To Be Dosed In Q4 Of 2023
Benzinga Newsdesk - Jun 21, 2023, 7:17AM

Wednesday, May 31, 2023

Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
Benzinga Insights - May 31, 2023, 11:00AM
Roth MKM Initiates Coverage On Unity Biotechnology with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk - May 31, 2023, 4:27AM

Friday, May 26, 2023

Where Unity Biotechnology Stands With Analysts
Benzinga Insights - May 26, 2023, 11:02AM
Citigroup Maintains Buy on Unity Biotechnology, Raises Price Target to $6
Benzinga Newsdesk - May 26, 2023, 6:41AM

Wednesday, May 10, 2023

HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $10 Price Target
Benzinga Newsdesk - May 10, 2023, 6:37AM

Tuesday, May 09, 2023

Recap: Unity Biotechnology Q1 Earnings
Benzinga Insights - May 9, 2023, 5:34PM
Unity Biotechnology Q1 EPS $(0.76) Beats $(1.08) Estimate
Benzinga Newsdesk - May 9, 2023, 5:10PM

Tuesday, April 25, 2023

Where Unity Biotechnology Stands With Analysts
Benzinga Insights - Apr 25, 2023, 9:01AM
Wedbush Maintains Outperform on Unity Biotechnology, Lowers Price Target to $3
Benzinga Newsdesk - Apr 25, 2023, 7:44AM

Monday, April 24, 2023

Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea
Vandana Singh - Apr 24, 2023, 11:34AM
UNITY Biotechnology Announces 48-Week Results From Phase 2 BEHOLD Study Of UBX1325 Showing A 'statistically significant and clinically meaningful improvement in Best Corrected Visual Acuity' At 48 Weeks
Benzinga Newsdesk - Apr 24, 2023, 7:04AM

Sunday, April 23, 2023

UNITY Biotechnology To Host Program Update To Discuss Its Lead Program In UBX1325 On Monday, April 24, 2023 At 8:00 A.M. ET
Charles Gross - Apr 23, 2023, 7:25PM

Monday, April 03, 2023

Stocks That Hit 52-Week Lows On Monday
Benzinga Insights - Apr 3, 2023, 1:36PM

Wednesday, March 29, 2023

Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights - Mar 29, 2023, 2:46PM
Why Shift Technologies Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Mar 29, 2023, 8:05AM

Tuesday, March 28, 2023

Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights - Mar 28, 2023, 1:43PM
Mizuho Maintains Buy on Unity Biotechnology, Lowers Price Target to $6
Benzinga Newsdesk - Mar 28, 2023, 12:28PM
Expert Ratings for Unity Biotechnology
Benzinga Insights - Mar 28, 2023, 10:02AM
Wedbush Maintains Outperform on Unity Biotechnology, Lowers Price Target to $5
Benzinga Newsdesk - Mar 28, 2023, 10:01AM
HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $10 Price Target
Benzinga Newsdesk - Mar 28, 2023, 6:30AM
Citigroup Maintains Buy on Unity Biotechnology, Lowers Price Target to $5
Benzinga Newsdesk - Mar 28, 2023, 6:08AM

Monday, March 27, 2023

Nasdaq Edges Lower; Unity Biotechnology Shares Plummet
Lisa Levin - Mar 27, 2023, 2:37PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Mar 27, 2023, 1:31PM
Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin - Mar 27, 2023, 1:22PM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved